SCHEMBL12419277

SCHEMBL12419277

CCCc1nc2ccc(B(O)O)cc2o1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.43
LPL P06858 2/20 0.42
LIPG Q9Y5X9 2/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
AAK1 Q2M2I8 1/20 0.40
ELANE P08246 1/20 0.40
ENPP2 Q13822 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
LMNA P02545 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.37
USP2 O75604 1/20 0.37
MAPK10 P53779 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CA1 P00915 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954162 1.00 MAPT (0.51) MAPTKDM4EALDH1A1LPLLIPG
SCHEMBL12419279 0.90 MEN1 (0.48) MAPTKDM4ELPLLIPGMEN1
SCHEMBL12419276 0.81 MAPT (0.55) MAPTKDM4ENPC1RAB9ALMNA
SCHEMBL17232968 0.80 MAPT (0.56) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL12419278 0.79 MAPT (0.42) MAPTKDM4EMEN1KMT2ANPC1
SCHEMBL5535594 0.78 MAPT (0.83) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL12419273 0.77 LMNA (0.54) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL5535590 0.76 MAPT (0.56) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL14619107 0.76 MAPT (0.56) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL29802262 0.76 MAPT (0.56) MAPTKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 MAPT 3395/4885KDM4E 1442/4885ALDH1A1 354/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 MAPT 3395/4885KDM4E 1442/4885ALDH1A1 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.